<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172067</url>
  </required_header>
  <id_info>
    <org_study_id>CR-09-063-AP-HF</org_study_id>
    <nct_id>NCT01172067</nct_id>
  </id_info>
  <brief_title>QuickOpt Chronic Study</brief_title>
  <official_title>Clinical Impact of Cardiac Resynchronization Therapy on Heart Failure Patients With QuickOpt and Echo Optimization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that QuickOpt optimization can be as an
      alternative method for CRTP/D patients' optimization in clinical practice through the
      comparison of the improvement differences between the CRTP/D patients with different
      optimization at 12 months after implantation.The hypothesis is that the Heart Remolding
      parameter (LVESV) improvement of patients using QuickOpt parameters at 12 months after
      implant is not inferior (10%) to the patients by Echo optimization。
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical studies have demonstrated that the AVTI from QuickOptTM related significantly to the
      max aorta VTI (AVTI) by Echo, the concordance correlation coefficient (CCC) was so high from
      0.96 to 0.99.

      But up to now, there are no clinical trials to evaluate mid-long term clinical outcome for
      CRTP/D patients by QuickOptTM and Echo optimization, this is indeed the main purpose of the
      study; in addition, the clinical impact, the status of arrhythmia and agents of all the
      enrolled patients, will be evaluated at 1 year after implant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Left Ventricular End Systolic Volume (LVESV) at 12 Months Compared to Baseline</measure>
    <time_frame>Baseline and12 months</time_frame>
    <description>The primary outcome is the percent change in LVESV at 12 months compared to baseline. This outcome measure is assessed through evaluation of echocardiograms at both baseline and 12 months, with a decrease in the percent change in LVESV at 12 months indicating clinical improvement. The percent change in patients with devices optimized with QuickOpt is compared with that of patients with devices optimized using standard echocardiography techniques to determine if one method of optimization results in a greater change in LVESV.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Quickopt Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the QuickOpt Group patients will be optimized by QuickOpt(IEGM);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Echocardiography group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the Echo Group patients will be optimized by Echo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy</intervention_name>
    <description>Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.</description>
    <arm_group_label>Quickopt Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimization using echocardiography</intervention_name>
    <description>Optimization of the AV/PV and VV delays using echocardiography</description>
    <arm_group_label>Echocardiography group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Patient meets current CRT-P indications and be implanted with an SJM CRT-P device
             with V-V timing and a compatible lead system

               -  Patient is able to provide written informed consent for study participation

        Exclusion Criteria:

          -  • Patient has limited intrinsic atrial activity (≤ 40 bpm)

               -  Patient has persistent or permanent AF

               -  Patient has a 2o or 3o heart block

               -  Patient's life expectancy is &lt;12 months

               -  Patient is &lt;18 years old

               -  Patient is pregnant

               -  Patient is on IV inotropic agents

               -  Patients who are ongoing other devices or agents study

               -  Patients with heart transplanted or waiting for heart transplant

               -  Patients with Hypertrophic and obstructive cardiomyopathy

               -  Patients with severe aortic valve and mitral valve stenosis or regurgitation
                  without replacement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <results_first_submitted>May 29, 2019</results_first_submitted>
  <results_first_submitted_qc>September 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2019</results_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRT</keyword>
  <keyword>heart failure</keyword>
  <keyword>optimization</keyword>
  <keyword>Timing cycle optimization methods</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Quickopt Group</title>
          <description>the QuickOpt Group patients will be optimized by QuickOpt(IEGM);
Cardiac Resynchronization Therapy: Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.</description>
        </group>
        <group group_id="P2">
          <title>Echocardiography Group</title>
          <description>the Echo Group patients will be optimized by Echo.
Optimization using echocardiography: Optimization of the AV/PV and VV delays using echocardiography</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>QuickOpt Group</title>
          <description>Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.</description>
        </group>
        <group group_id="B2">
          <title>Echocardiography Group</title>
          <description>Optimization using echocardiography: Optimization of the AV/PV and VV delays using echocardiography</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="198"/>
            <count group_id="B2" value="194"/>
            <count group_id="B3" value="392"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.38" spread="11.77"/>
                    <measurement group_id="B2" value="59.21" spread="11.36"/>
                    <measurement group_id="B3" value="60.17" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Left Ventricular End Systolic Volume (LVESV) at 12 Months Compared to Baseline</title>
        <description>The primary outcome is the percent change in LVESV at 12 months compared to baseline. This outcome measure is assessed through evaluation of echocardiograms at both baseline and 12 months, with a decrease in the percent change in LVESV at 12 months indicating clinical improvement. The percent change in patients with devices optimized with QuickOpt is compared with that of patients with devices optimized using standard echocardiography techniques to determine if one method of optimization results in a greater change in LVESV.</description>
        <time_frame>Baseline and12 months</time_frame>
        <population>A total of 108 patients in the QuickOpt group and 118 patients in the Echocardiography group had LVESV measurements at both baseline and 12 months to allow comparison of the percent change in LVESV.</population>
        <group_list>
          <group group_id="O1">
            <title>QuickOpt Group</title>
            <description>Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.</description>
          </group>
          <group group_id="O2">
            <title>Echocardiography Group</title>
            <description>Optimization using echocardiography: Optimization of the AV/PV and VV delays using echocardiography</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Left Ventricular End Systolic Volume (LVESV) at 12 Months Compared to Baseline</title>
          <description>The primary outcome is the percent change in LVESV at 12 months compared to baseline. This outcome measure is assessed through evaluation of echocardiograms at both baseline and 12 months, with a decrease in the percent change in LVESV at 12 months indicating clinical improvement. The percent change in patients with devices optimized with QuickOpt is compared with that of patients with devices optimized using standard echocardiography techniques to determine if one method of optimization results in a greater change in LVESV.</description>
          <population>A total of 108 patients in the QuickOpt group and 118 patients in the Echocardiography group had LVESV measurements at both baseline and 12 months to allow comparison of the percent change in LVESV.</population>
          <units>Percent change in LVESV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.69" spread="33.86"/>
                    <measurement group_id="O2" value="-25.13" spread="36.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Quickopt Group</title>
          <description>the QuickOpt Group patients will be optimized by QuickOpt(IEGM);
Cardiac Resynchronization Therapy: Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.</description>
        </group>
        <group group_id="E2">
          <title>Echocardiography Group</title>
          <description>the Echo Group patients will be optimized by Echo.
Optimization using echocardiography: Optimization of the AV/PV and VV delays using echocardiography</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Death; not related to study devices</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hopitalization</sub_title>
                <description>Patient hopitalized then expired; death not related to study devices</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Heart Failure Deterioration; Death</sub_title>
                <description>Heart failure deteriorated; patient expired; SAE not related to study devices.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest, death</sub_title>
                <description>Patient sustained cardiopulmonary arrest. Patient expired. The death is not related to study devices.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Junctional rhythm, hypotension</sub_title>
                <description>Patient sustained junctional rhythm and low blood pressure. The event was considered related to study device. The pace maker was re-interrogated.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Heart failure deterioration, hospitalization</sub_title>
                <description>Heart failure deteriorated. Patient hospitalized. The event is not related to study devices.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Heart failure deterioration, elevated left ventricular pacing threshold</sub_title>
                <description>Heart failure deteriorated. Left ventricular pacing threshold increased. The event is not related to study devices.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Heart failure deterioration, myocardial infarction, venous thrombosis, death</sub_title>
                <description>Heart failure deteriorated. Patient sustained myocardial infarction and venous thrombosis. Patient expired. The death is not related to study devices.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Heart failure deterioration, phrenic nerve stimulation</sub_title>
                <description>Heart failure deteriorated. Patient experienced phrenic nerve stimulation. The event was considered related to study devices.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia, staged heart bypass surgery</sub_title>
                <description>Patient was diagnosed with myocardial ischemia and underwent staged heart bypass surgery. The event is not related to study devices.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Chest distress, short breaths</sub_title>
                <description>Patient stated chest distress and short breaths. Patient was hospitalized. The event is not related to study devices.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Haematoma, low right atrial lead sensing</sub_title>
                <description>Patient sustained haematoma; the right atrial lead sensing decreased. The event is not related to study devices.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>pacemaker pocket ulceration</sub_title>
                <description>Pacemaker pocket skin ulceration. The event is not related to study devices.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>pacemaker reject</sub_title>
                <description>Patient's body rejected pacemaker. The event is not related to study devices.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral hemorrhage, death</sub_title>
                <description>Patient sustained cerebral hemorrhage. Patient expired. The death is not related to study devices.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Phrenic nerve stimulation</sub_title>
                <description>Patient experience phrenic nerve stimulation. The event is not related to study devices.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Elevated left ventricular pacing threshold</sub_title>
                <description>Left ventricular pacing threshold increased.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Coronary sinus dissection</sub_title>
                <description>Patient sustained coronary sinus dissection; the event is not related to study devices.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Right ventricular lead dislocation/displacement</sub_title>
                <description>Right ventricular lead dislocation/displacement; the event is not related to study devices.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Right atrial lead dislocation/displacement</sub_title>
                <description>Right atrial lead dislocation/displacement; the event is not related to study devices.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Left ventricular lead dislocation/displacement</sub_title>
                <description>Left ventricular lead dislocation/displacement; the event is related to study devices.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Elevated pacing threshold of left ventricular lead; lead dislocation/displacem</sub_title>
                <description>Elevated pacing threshold of left ventricular lead; lead dislocation/displacem; the event is related to study devices.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <description>Patient experienced anaphylactic shock; the event is not related to study devices.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection at pacing system</sub_title>
                <description>Patient sustain infection at pacing system; the event is not related to study devices.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clay Cohorn, Program Director</name_or_title>
      <organization>CRT, Global Clinical Affairs, Cardiac Arrhythmias and Heart Failure, Abbott Medical Devices</organization>
      <phone>+1 972 309 8087</phone>
      <email>clay.cohorn@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

